Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

When elimination leaves patients behind: clinical, serologic and molecular evidence of a human African trypanosomiasis case highlighting diagnostic, surveillance and treatment gaps in Nigeria.

Created on 19 Nov 2026

Authors

Chinwe Chukwudi, Jonadab Chinwendu, Omolara Adenekan, Oluwamayowa Opara, Babatunde Joshua, Edward Nwanegbo, Michael Grigg, Silvanus Anika

Published in

Infectious diseases of poverty. Volume 15. Issue 1. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Despite substantial progress toward elimination, human African trypanosomiasis (HAT) remains vulnerable to under-recognition in low-surveillance settings. Nigeria, historically endemic for HAT, has reported very few recent cases, which raises questions about whether declining incidence reflects true interruption of transmission or limitations in surveillance and diagnostic systems. Here, we report a case that illustrates the unique challenges of case detection and surveillance, confirmation and treatment in Nigeria, which resulted in poor patient outcomes and ongoing transmission that may hinder sustainable HAT elimination.
A 17-year-old male from Imo State, Nigeria, first developed recurrent seizures in 2020 at the age of 12 and received treatment for epilepsy for approximately 4 years before progressive neurological deterioration prompted further investigations for HAT. Serological and molecular testing supported infection with Trypanosoma brucei, and cerebrospinal fluid findings were consistent with second-stage HAT. Tested family members also showed positive serological and molecular results, suggesting possible undetected transmission within the household. Despite the cumulative clinical, serologic and molecular evidence, treatment was not initiated owing to prevailing operational practices in the country. Patient's symptoms remain unabated with continued anti-epilepsy treatment and no access to HAT medications.
This case demonstrates how prolonged clinical misdiagnosis, gaps in surveillance, and barriers to accessing treatment can delay recognition and management of HAT in low-prevalence settings, especially in the absence of parasitological confirmation. It also highlights broader challenges facing elimination programmes, illustrating how the gap between international diagnostic/treatment guidelines and operational practice affects patient care. The detection of infection markers among family members further raises concern about under-recognized transmissions in Nigeria. Strengthening clinician awareness, enhancing surveillance systems, conducting family-based case investigations, and ensuring timely access to adequate diagnosis and treatment will be essential for achieving equitable HAT elimination.

PMID:
43053212
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement